CN102046166B - 用于治疗干眼症的β-转角模拟肽环状化合物 - Google Patents

用于治疗干眼症的β-转角模拟肽环状化合物 Download PDF

Info

Publication number
CN102046166B
CN102046166B CN2009801190689A CN200980119068A CN102046166B CN 102046166 B CN102046166 B CN 102046166B CN 2009801190689 A CN2009801190689 A CN 2009801190689A CN 200980119068 A CN200980119068 A CN 200980119068A CN 102046166 B CN102046166 B CN 102046166B
Authority
CN
China
Prior art keywords
compound
scopolamine
day
dry eye
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2009801190689A
Other languages
English (en)
Chinese (zh)
Other versions
CN102046166A (zh
Inventor
G·卡姆伯利德吉
K·米罗维特施
T·拉玛
H·U·萨拉戈维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mimetogen Pharmaceuticals Inc
Original Assignee
Mimetogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mimetogen Pharmaceuticals Inc filed Critical Mimetogen Pharmaceuticals Inc
Publication of CN102046166A publication Critical patent/CN102046166A/zh
Application granted granted Critical
Publication of CN102046166B publication Critical patent/CN102046166B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2009801190689A 2008-04-04 2009-04-03 用于治疗干眼症的β-转角模拟肽环状化合物 Active CN102046166B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12303608P 2008-04-04 2008-04-04
US61/123,036 2008-04-04
US20887309P 2009-02-27 2009-02-27
US61/208,873 2009-02-27
PCT/US2009/002121 WO2009123761A1 (en) 2008-04-04 2009-04-03 Beta-turn peptidomimetic cyclic compounds for treating dry eye

Publications (2)

Publication Number Publication Date
CN102046166A CN102046166A (zh) 2011-05-04
CN102046166B true CN102046166B (zh) 2012-10-17

Family

ID=40897413

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801190689A Active CN102046166B (zh) 2008-04-04 2009-04-03 用于治疗干眼症的β-转角模拟肽环状化合物

Country Status (9)

Country Link
US (4) US8293713B2 (https=)
EP (1) EP2271337B1 (https=)
JP (2) JP5480242B2 (https=)
KR (1) KR101565185B1 (https=)
CN (1) CN102046166B (https=)
AU (1) AU2009232352B2 (https=)
CA (1) CA2720141C (https=)
ES (1) ES2521515T3 (https=)
WO (1) WO2009123761A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521515T3 (es) * 2008-04-04 2014-11-12 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos con giro beta para tratar el ojo seco
US9115179B2 (en) * 2012-06-22 2015-08-25 Mimetogen Pharmaceuticals Inc. Synthesis of beta-turn peptidomimetic cyclic compounds
KR20150004652A (ko) 2013-07-03 2015-01-13 삼성디스플레이 주식회사 표시 패널, 이를 포함하는 표시 장치 및 이를 이용하는 영상 표시 방법
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
CN113230021A (zh) 2015-01-12 2021-08-10 科达莱昂治疗公司 微滴递送设备和方法
CN107530509A (zh) 2015-04-10 2018-01-02 科达莱昂治疗公司 具有可替换安瓿的压电分配器
AU2016290654C1 (en) * 2015-07-09 2021-11-11 Mimetogen Pharmaceuticals, Inc. Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
KR101718733B1 (ko) 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
WO2017152027A1 (en) 2016-03-04 2017-09-08 Rynerson James M Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation
CN109906120A (zh) 2017-01-20 2019-06-18 科达莱昂治疗公司 压电流体分配器
WO2019113483A1 (en) 2017-12-08 2019-06-13 Kedalion Therapeutics, Inc. Fluid delivery alignment system
CN110092799B (zh) * 2018-01-29 2021-11-12 广州丹康医药生物有限公司 一种环状化合物、其制备方法和应用
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
US20190314197A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
WO2020010116A1 (en) 2018-07-03 2020-01-09 Kedalion Therapeutics, Inc. Topical ocular delivery devices and methods for using the same
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
EP4120973A4 (en) 2020-04-17 2024-04-17 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
CN115768384A (zh) 2020-04-17 2023-03-07 科达隆治疗公司 流体动力致动的不含防腐剂分配系统
WO2022256394A2 (en) * 2021-06-02 2022-12-08 The Texas A&M University System Selective small molecule agonists and partial agonists of trk receptors
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023069549A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052843A1 (en) * 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8917217D0 (en) * 1989-07-27 1989-09-13 Smith & Nephew Ophthalmic compositions
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
JP2001064198A (ja) 1999-08-24 2001-03-13 Teika Seiyaku Kk 角膜疾患治療剤
EP1734052B1 (en) 2005-06-13 2009-02-18 Primm S.R.L. Heterodimeric peptide compounds displaying NGF activity and their use to treat neurodegenerative disorders
EP1921087A1 (en) 2006-11-10 2008-05-14 Primm S.R.L. Process for the preparation of cyclic peptides
JP5576659B2 (ja) * 2006-12-05 2014-08-20 ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ Ｔｒｋレセプター調節因子の使用方法
ES2521515T3 (es) * 2008-04-04 2014-11-12 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos con giro beta para tratar el ojo seco
CA2752891C (en) * 2009-02-27 2018-08-21 Mimetogen Pharmaceuticals Inc. Peptidomimetic cyclic compounds for treating retinitis pigmentosa
US9115179B2 (en) * 2012-06-22 2015-08-25 Mimetogen Pharmaceuticals Inc. Synthesis of beta-turn peptidomimetic cyclic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052843A1 (en) * 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A. Lambiase等.Efficacy of topical nerve growth factor treatment in dogs affected by dry eye.《Graefe’s Arch Clin Exp Ophthalmol》.2005,第243卷151–155. *

Also Published As

Publication number Publication date
CA2720141A1 (en) 2009-10-08
JP5480242B2 (ja) 2014-04-23
US8293713B2 (en) 2012-10-23
US9156882B2 (en) 2015-10-13
AU2009232352B2 (en) 2013-09-05
EP2271337B1 (en) 2014-09-03
US9707267B2 (en) 2017-07-18
EP2271337A1 (en) 2011-01-12
ES2521515T3 (es) 2014-11-12
US8748391B2 (en) 2014-06-10
US20120322747A1 (en) 2012-12-20
US20110105410A1 (en) 2011-05-05
KR101565185B1 (ko) 2015-11-02
CA2720141C (en) 2014-01-28
KR20110010712A (ko) 2011-02-07
JP5870348B2 (ja) 2016-02-24
WO2009123761A1 (en) 2009-10-08
JP2011516477A (ja) 2011-05-26
HK1152898A1 (en) 2012-03-16
JP2014080447A (ja) 2014-05-08
CN102046166A (zh) 2011-05-04
AU2009232352A1 (en) 2009-10-08
US20140274910A1 (en) 2014-09-18
US20160082072A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
CN102046166B (zh) 用于治疗干眼症的β-转角模拟肽环状化合物
US20170224771A1 (en) Histatins as therapeutic agents for ocular surface disease
IL259562A (en) Aminophosphinic derivatives for preventing and treating eye pain
US20100113456A1 (en) Therapeutic agent for corneal disease
CN102333537B (zh) 用于治疗色素性视网膜炎的模拟肽环状化合物
WO2010107069A1 (ja) アミノ酸含有眼科用組成物
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies
HK1152898B (en) Beta-turn peptidomimetic cyclic compounds for treating dry eye
Tu et al. Dry eye
US20230134843A1 (en) Treatment of stem cell deficiency
CN118434434A (zh) 用于治疗、预防、抑制、改善眼科病状或延缓其发作的方法和包括肽模拟物的组合物
WO2023048174A1 (ja) 角膜疾患治療剤
HK1161980A (en) Peptidomimetic cyclic compounds for treating retinitis pigmentosa

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Cumberlidge Garth

Inventor after: Meerovitch Karen

Inventor after: Lama Teresa

Inventor after: Saragovi H. Uri

Inventor before: Cumberlidge Garth

Inventor before: Meerovitch Karen

Inventor before: Lama Teresa

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: GARTH CUMBERLIDGE MIRVITESSE K. T.LARMA TO: GARTH CUMBERLIDGE MIRVITESSE K. T.LARMA URI SARAGOVI H

C14 Grant of patent or utility model
GR01 Patent grant